Vericel (VCEL) Tops Q3 EPS by 4c, Beats on Revenue; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
November 8, 2023 7:55 AM ESTRecord Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year
MACI Revenue Growth of 21% to $37.6 Million
Full-Year 2023 Revenue Guidance Raised to $192.5-197.5 Million
Conference Call Today at 8:30am Eastern Time
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2023.
Third Quarter 2023 Financial Highlights... More
